Low Molecular Weight Heparin in Pregnancies With Unexplained Stillbirths
Second Generation Low Molecular Weight Heparin (Bemiparin) as a Prophylactic for Management of Subsequent Pregnancy After an Unexplained Stillbirth: A Clinical Comparative Study
PhaseEarly Phase 1
Lead SponsorHawler Medical University
StatusCompleted No Results Posted
Bemiparin for pregnant women with abnormal umbilical artery Doppler ultrasound
152 women with history of unexplained stillbirths were identified , umbilical arty Doppler ultrasound was conducted for them at 20-22 weeks gestation . they were divided into two group , group one are those with abnormal resistant index (= or more than 0.6) thy received Bemiparin 2500 IU subcutaneously daily up to 24 hours before delivery .
Group 2 with normal umbilical artery resistant index received no any interventions just routine antenatal follow up .
second generation low molecular weight Heparin
multivitamins and routine antenatal follow up
Women with high resistant index of umbilical artery received the intervention Bemiparin Sodium 2,500 IU anti Xa/0.2 ml solution for injection in pre-filled syringe provided for each woman . The injections were received daily since 20 weeks gestation and up to 24 hours before delivery Other Name: Hibor; Laboratories Rovi pharmaceuticals
Normal umbilical arty resistant index group received only multivitamins and routine antenatal follow up
Inclusion Criteria: Second pregnancy after previous unexplained fetal death Singleton pregnancy No any medical disorders during pregnancy like diabetes or Systemic Lupus Erythematosus Normally located placenta No congenital fetal anomalies Patient accept to participate Exclusion Criteria: Confirmed thrombophilia Twin pregnancies Refused to participate